E
Eytan M. Stein
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 226
Citations - 8160
Eytan M. Stein is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 36, co-authored 174 publications receiving 5409 citations. Previous affiliations of Eytan M. Stein include University of Texas MD Anderson Cancer Center & Northwestern University.
Papers
More filters
Journal ArticleDOI
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Daniel A. Pollyea,Amir T. Fathi,Gail J. Roboz,Gail J. Roboz,Jessica K. Altman,Richard Stone,Daniel J. DeAngelo,Ross L. Levine,Ian W. Flinn,Hagop M. Kantarjian,Robert H. Collins,Manish R. Patel,Arthur E. Frankel,Anthony S. Stein,Mikkael A. Sekeres,Ronan T. Swords,Bruno C. Medeiros,Christophe Willekens,Christophe Willekens,Paresh Vyas,Alessandra Tosolini,Qiang Xu,Robert Knight,Katharine E. Yen,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Martin S. Tallman,Martin S. Tallman +31 more
TL;DR: Inducing differentiation of myeloblasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib, a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.
Journal ArticleDOI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D. DiNardo,Eytan M. Stein,S. de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Ronan T. Swords,Robert H. Collins,Gabriel N. Mannis,Daniel A. Pollyea,William B. Donnellan,Amir T. Fathi,A. Pigneux,Harry P. Erba,Gabrielle T. Prince,Anthony S. Stein,Geoffrey L. Uy,James M. Foran,Elie Traer,Robert K. Stuart,Martha Arellano,James L. Slack,Mikkael A. Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine E. Yen,Stephanie M. Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Samuel V. Agresta,Bin Wu,Eyal C. Attar,Martin S. Tallman,Richard Stone,Hagop M. Kantarjian +39 more
TL;DR: In patients with advanced IDH1‐mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment‐related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission.
Journal ArticleDOI
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.
Hartmut Döhner,Andrew H. Wei,Frederick R. Appelbaum,Charles Craddock,Courtney D. DiNardo,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Lucy A. Godley,Robert P. Hasserjian,Richard A. Larson,Ross Levine,Yasushi Miyazaki,Dietger Niederwieser,Gert J. Ossenkoppele,Christoph Röllig,Jorge Sierra,Eytan M. Stein,Martin S. Tallman,Hwei-Fang Tien,Jianxiang Wang,Agnieszka Wierzbowska,Bob Löwenberg +22 more
TL;DR: This update includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations for acute myeloid leukemia in adults, which are widely recognized among physicians and investigators.
Journal ArticleDOI
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein,Guillermo Garcia-Manero,David A. Rizzieri,Raoul Tibes,Jesus G. Berdeja,Michael R. Savona,Mojca Jongen-Lavrenic,Jessica K. Altman,Blythe Thomson,Stephen J. Blakemore,Scott R. Daigle,Nigel J. Waters,A. Benjamin Suttle,Alicia Clawson,Roy M. Pollock,Andrei V. Krivtsov,Scott A. Armstrong,Jorge DiMartino,Eric Hedrick,Bob Löwenberg,Martin S. Tallman +20 more
TL;DR: Overall, 2 patients experienced complete remission at 54 mg/m2 per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in MLL-r leukemia patients.
Journal ArticleDOI
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael Amatangelo,Lynn Quek,Alan Shih,Eytan M. Stein,Mikhail Roshal,Muriel D. David,Benoit S. Marteyn,Noushin Farnoud,Stéphane de Botton,Olivier A. Bernard,Bin Wu,Katharine E. Yen,Martin S. Tallman,Elli Papaemmanuil,Virginie Penard-Lacronique,Anjan Thakurta,Paresh Vyas,Ross L. Levine +17 more
TL;DR: In this article, the authors measured 2-HG, mIDH2 allele burden, and cooccurring somatic mutations in sequential patient samples from the clinical trial and correlated these with clinical response.